Phi Life Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Phi Life Sciences is a privately held, revenue-generating laboratory services and diagnostics company founded in 2018. Its core business is divided into clinical diagnostic services for infectious diseases and genetic testing, and contract laboratory services supporting pharmaceutical and diagnostic companies with validation and clinical trial testing. The company leverages its CLIA lab to bridge innovation from the bench to commercial application, though it appears to have pivoted from its original small molecule/drug delivery focus to a service-oriented diagnostic model. Its near-term strategy relies on its COVID-19 testing franchise and expanding its menu of molecular diagnostic panels.

Infectious DiseaseOncologyOther Genetic Disorders

Technology Platform

CLIA/GLP-compliant laboratory infrastructure for molecular assay validation, development, and commercialization. Utilizes RT-PCR and other molecular methods to provide diagnostic testing services and support for third-party product development.

Opportunities

The growing demand for precision medicine and molecular diagnostics creates a tailwind for its CGx and PGx testing services.

Its niche laboratory services model, which bridges validation and commercialization, positions it to capture value from the growing pipeline of novel diagnostic devices and assays developed by biotech and pharma partners.

Risk Factors

Revenue is vulnerable to the sharp decline in COVID-19 testing demand.

The company faces intense competition from large national labs and CROs in both its clinical diagnostics and contract service businesses.

Its success is highly dependent on securing a steady stream of new validation contracts and commercial partnerships.

Competitive Landscape

In clinical diagnostics, Phi Life Sciences competes with giant national laboratories (Quest Diagnostics, LabCorp), large hospital labs, and specialized molecular diagnostic companies. In its laboratory services division, it competes with global CROs (IQVIA, PPD) and specialized clinical trial laboratory service providers. Its differentiation lies in its smaller size offering potentially more tailored service and its integrated model of validation followed by in-house commercialization.

More companies in Diagnostics & Precision Medicine →More companies in United States →